Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07076121 · ClinicalTrials.gov registry record · Phase 2

A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

A Phase 2 study of Pancreatic Ductal Adenocarcinoma, sponsored by Bristol-Myers Squibb.

Recruiting
Registry status
Phase 2
Development phase
470
Enrollment target
20
Study locations

NCT07076121 is a Phase 2 study of Pancreatic Ductal Adenocarcinoma that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 470 participants, below the 595-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (21% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07076121, a Phase 2 study of Pancreatic Ductal Adenocarcinoma, is actively recruiting participants, sponsored by Bristol-Myers Squibb.

RECRUITING
Registry status
Phase 2
Development phase
470 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to assess the safety and efficacy of BMS-986504, a selective, MTA-cooperative PRMT5 inhibitor, in combination with Nab-paclitaxel/Gemcitabine (nab-p/gem) versus placebo in combination with nab-p/gem, in participants with untreated metastatic Pancreatic Ductal Adenocarcinoma (PDAC) with homozygous methylthioadenosine phosphorylase (MTAP) deletion.

Conditions Studied

Pancreatic Ductal Adenocarcinoma

Interventions

  • DRUG Placebo
  • DRUG Gemcitabine
  • DRUG Nab-paclitaxel
  • DRUG BMS-986504

Study Locations (20)

Florida

  • Local Institution - 0369 - Jacksonville
  • Local Institution - 0139 - Jacksonville
  • Local Institution - 0132 - Tampa

Arizona

  • Local Institution - 0142 - Phoenix
  • Local Institution - 0365 - Tucson

California

  • Local Institution - 0373 - La Jolla
  • Local Institution - 0157 - San Francisco

Georgia

  • Local Institution - 0367 - Atlanta
  • Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital - Marietta

Maryland

  • Local Institution - 0371 - Baltimore
  • Local Institution - 0145 - Baltimore

Michigan

  • Local Institution - 0191 - Detroit
  • The Cancer & Hematology Centers - Grand Rapids

Arkansas

  • Highlands Oncology Group - Springdale

Idaho

  • St. Luke's Cancer Institute: Boise - Boise

Trial Details

FieldValue
Enrollment Target 470 participants
Start Date 2025-10-23
Est. Completion 2029-05-03
Phase Phase 2

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07076121

The ClinicalTrials.gov registry entry for NCT07076121 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 470 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 595-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (21% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pancreatic Ductal Adenocarcinoma appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.

NCT07076121 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, Arizona, California.

Frequently Asked Questions

What is clinical trial NCT07076121 about?

NCT07076121 is a clinical study titled "A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)". The purpose of this study is to assess the safety and efficacy of BMS-986504, a selective, MTA-cooperative PRMT5 inhibitor, in combination with Nab-paclitaxel/Gemcitabine (nab-p/gem) versus placebo in combination with nab-p/gem, in participants with untreated metastatic Pancreatic Ductal Adenocarcin...

What is the current status of trial NCT07076121?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 470 participants. The study started on 2025-10-23. Estimated completion is 2029-05-03.

What conditions does trial NCT07076121 study?

This clinical trial studies the following conditions: Pancreatic Ductal Adenocarcinoma.

What interventions are being tested in trial NCT07076121?

The interventions under investigation include: Placebo (DRUG), Gemcitabine (DRUG), Nab-paclitaxel (DRUG), BMS-986504 (DRUG).

Who is sponsoring clinical trial NCT07076121?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07076121 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pancreatic Ductal Adenocarcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pancreatic Ductal Adenocarcinoma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.